Heart experts call for urgent action to implement new findings on cholesterol-lowering treatment

July 04, 2002

Research reported in Saturday 6 July Lancet is set to revolutionise the way cholesterol-lowering drugs are prescribed. It shows that using "statin" drugs to lower blood cholesterol levels protects a far wider range of people at risk of heart attacks and strokes than had previously been thought to benefit. These findings should lead to major changes in treatment guidelines, preventing tens of thousands of deaths each year, a London news briefing has been told.

At present, statins are often restricted to people who have heart disease and elevated cholesterol levels. But, new findings from the UK's 20,000-patient Heart Protection Study* show that statins also cut the risks of heart attacks and strokes in people who have diabetes, or have narrowing of arteries in their legs, or have had a stroke. Most remarkably, the study found substantial benefits even among those high-risk patients considered to have "normal" or "low" cholesterol levels. It provides definite evidence that guidelines should be changed so that - irrespective of the blood cholesterol level - a statin is considered for anybody at increased risk of either heart attacks or strokes.

"The clear message from this study is: 'Treat risk - not cholesterol level', "said Professor Sir Charles George, Medical Director of the British Heart Foundation - the UK's leading heart charity. He called for an urgent review of national and international guidelines on statin use by government organisations, such as the National Institute of Clinical Excellence (NICE) in the UK and the National Institutes of Health (NIH) in the USA, as well as by professional bodies, such as the European Society of Cardiology (ESC) and the American Heart Association (AHA).

The study overturns conventional wisdom in a number of other areas. For example, current guidelines say that there is little evidence that statins help older individuals. By deliberately studying large numbers of older people, the researchers were able to show that cholesterol-lowering with statins was just as effective for the over 70s as for those in middle age.

Likewise, not many women had been included in previous studies so there was little direct evidence on the benefits and safety of statins in women. With more than 5,000 women included in the Heart Protection Study, it has been able to show that statins work just as well for women as for men.

HPS lead investigator Professor Rory Collins said: " HPS shows unequivocally that statins can produce substantial benefit in a very much wider range of high-risk people than had been thought. These new findings are relevant to the treatment of some hundreds of millions of people worldwide. If now, as a result, an extra 10 million high-risk people were to go onto statin treatment, this would save about 50,000 lives a year - that's a thousand each week. In addition, this would prevent similar numbers of people from suffering non-fatal heart attacks or strokes."

The HPS team estimates that implementing these new findings fully would more than triple the numbers of people benefiting from statins. In the UK, the numbers treated with statins would increase from a current figure of less than 1 in 20 of the population aged over 40 (or about 1 million people) to about one in 8 (about 3 million people). This would save an extra 10,000 lives each year.

An outline of the study findings was presented at the American Heart Association conference in Los Angeles last November. Now that the detailed results are published in the Lancet, the way is open for a review of official guidelines and for doctors to change their prescribing practice. This could have a significant impact in reducing the high rates of heart attacks and strokes in the UK and other developed countries. It would also be important for many developing countries where the rates of heart attacks and strokes are already high or are rising rapidly, and where diabetes is becoming increasingly common.

Dr Richard Horton, editor of the Lancet, who chaired the news briefing, backed the call for a review of the guidelines. "These findings should tear up the rule-book on statin prescribing," he said. "They are the most important and far-reaching results for the treatment and prevention of heart disease and strokes that we have seen in a generation."

One of the most encouraging aspects of the study was that the majority of people now shown to benefit from statins would already be known to their doctors because of their past medical history. HPS clinical coordinator Dr Jane Armitage said: "Implementing these findings does not require massive public health education campaigns by governments. It simply needs the guidelines to be changed so that doctors check their medical records and identify those patients with vascular disease or diabetes who we now know would benefit substantially from statin therapy."

Sir George Radda, Chief Executive of the UK's Medical Research Council, said the implications for managing health were good for both patients and healthcare professionals alike. "Through a single large-scale, well-designed trial we have been able to identify a whole new set of patients with a variety of conditions who can be helped by statins," he said.

Another bonus from HPS was that it established firmly that statin treatment is safe. Professor Peter Sleight, deputy chair of the HPS Steering Committee, said: "HPS should reassure doctors and patients about both the safety and the benefits of statins. It provides clear evidence that statin use safely cuts the risks not just of heart attacks but also of future strokes by about one-third. These findings open the door to treatment for many patients who are currently unlikely to receive a statin in the UK or elsewhere." The research team is currently analysing the financial implications of such changes in prescribing patterns. Said Professor Collins: "We can't yet say exactly how cost-effective implementing these findings would be and we do recognise that the drug costs will be significant**. But, we believe that the level of benefit in these high-risk patients is so great that treating them will be extremely cost-effective. Moreover, the benefits of statins are additional to those of other treatments (such as aspirin) that are already used to prevent heart attacks and strokes."

HPS also assessed the effects of using antioxidant vitamin supplements (600mg vitamin E, 250mg vitamin C and 20mg beta-carotene daily) in people at high risk of vascular disease. Those results are also published today in the Lancet. Although this supplement did increase blood vitamin concentrations substantially, it did not produce any significant reductions in the five-year risk of heart attacks, strokes, cancers or other major outcomes. However, the study did provide strong 5-year safety evidence. In particular, the vitamins did not produce any excess risk of strokes due to bleeding or of cancers at any site. This contradicts the apparent adverse trends in some other studies of vitamin E and beta-carotene.

* The MRC/BHF Heart Protection Study involved more than 20,000 volunteers aged 40-80 who were at high risk of coronary heart disease, but for whom there was substantial uncertainty about the balance of benefits and safety of cholesterol-lowering therapy. It specifically targeted groups in which there was little direct evidence of benefit - including women, the over 70s, people with diabetes, those with non-coronary vascular disease, and those with average or below-average cholesterol levels. Volunteers were randomly allocated to receive either 40mg daily simvastatin as cholesterol-lowering therapy, or matching dummy tablets (and, separately, were randomly allocated to receive vitamin supplements or matching dummy capsules). Study treatment and follow-up continued for an average of five years in 69 UK hospitals.

Funding of £21 million was provided by the UK's Medical Research Council, the UK British Heart Foundation, and the pharmaceutical companies Merck & Co. Inc. and Roche Vitamins Ltd. The study was, however, designed, conducted and analysed entirely independently of all funding sources by the Clinical Trial Service Unit of Oxford University.

** Currently, 40mg daily simvastatin (or an equivalent dose of another statin) costs approximately £1 per day in the UK and $4 per day in the US. The patent for lovastatin (Mevacor) expired at the end of 2001, and the patent for simvastatin (Zocor) expires in most of Europe (including the UK) in mid-2003 and in the US in 2006.

Summary of major findings of the Heart Protection Study

• Cholesterol-lowering with statin treatment reduced the risk of heart attacks and strokes by at least one third, as well as reducing the need for arterial surgery, angioplasty and amputations.

• Substantial reductions in these "major vascular events" were found in a very wide range of high-risk patients for whom there had previously been uncertainty about using cholesterol-lowering treatment, including:• About 5 years of statin treatment typically prevented these major vascular events in:Implications

Based on WHO estimates of the numbers of people with coronary heart disease, stroke and diabetes, it can be estimated that the results are relevant to the treatment of some hundreds of millions of people worldwide (see table). If an extra 10 million high-risk people were to start statin treatment this would save about 50,000 lives each year and would prevent similar numbers from suffering non-fatal heart attacks or strokes.

Global statistics*WHO Global Health Statistics (Murray CJL & Lopez AD, 1996): Estimates of numbers of people at all ages with coronary heart disease (angina), with stroke and with diabetes in 1990. NOTE: Some people may have more than one of these conditions and so be included in more than one column (i.e. there is some "double counting" due to overlap), but similar statistics are not readily available for people with other occlusive arterial disease (which would tend to under-estimate the size of the population to which the study results are relevant).

†Established Market Economies are Australia, Canada, Europe, Japan, New Zealand and US. WHO prevalence estimates for countries or areas within regions are not currently available, but (based on population size) the numbers of people with these conditions would be expected to be about 17M in US, 26M in Europe and 4M in UK alone.
-end-


Clinical Trial Service Unit, Oxford University

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.